The Complex Role of Gut Microbiota in Systemic Lupus Erythematosus and Lupus Nephritis: From Pathogenetic Factor to Therapeutic Target

Microorganisms, Год журнала: 2025, Номер 13(2), С. 445 - 445

Опубликована: Фев. 18, 2025

The role of gut microbiota (GM) and intestinal dysbiosis in triggering the onset and/or modulating severity progression lupus nephritis (LN) has been object intense research over last few years. Some alterations at phyla level, such as abundance Proteobacteria reduction Firmicutes/Bacteroidetes (F/B) ratio α-diversity have consistently reported systemic erythematosus (SLE), whereas a more specific ascribed to some species (Bacteroides thetaiotaomicron Ruminococcus gnavus) LN. Underlying mechanisms include microbial translocation through "leaky gut" subsequent molecular mimicry, immune dysregulation (alteration IFNγ levels balance between Treg Th17 subsets), epigenetic interactions. Levels bacterial metabolites, butyrate other short-chain fatty acids (SCFAs), appear play key Beyond components GM, virome mycobiome are also increasingly recognized important players modulation an response. On hand, microbiota-based therapy appears promising includes diet, prebiotics, probiotics, symbiotics, fecal transplantation (FMT). could correct critical alterations, F/B Treg/Th17 imbalance, blunt production autoantibodies renal damage. Despite current limits, GM is emerging powerful environmental factor that be harnessed interfere with leading SLE, preventing flares organ damage, including aim this review provide state-of-the-art analysis SLE LN on one while exploring possible therapeutic manipulation control disease hand.

Язык: Английский

---

Gut Microbiota Modulation: A Novel Strategy for Rheumatoid Arthritis Therapy

Biomolecules, Год журнала: 2024, Номер 14(12), С. 1653 - 1653

Опубликована: Дек. 23, 2024

Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to joint inflammation, progressive tissue damage and significant disability, severely impacting patients’ quality of life. While the exact mechanisms underlying RA remain elusive, growing evidence suggests strong link between intestinal microbiota dysbiosis disease’s development progression. Differences in microbial composition healthy individuals patients point role gut modulating immune responses promoting inflammation. Therapies targeting restoration have demonstrated promise improving treatment efficacy, enhancing patient outcomes slowing However, complex interplay pathways requires further investigation establish causative relationships mechanisms. Here, we review current understanding microbiota’s pathogenesis its potential as therapeutic target.

Язык: Английский

---

Editorial commentary on the special issue of immunology and endocrinology

Journal of Biomedical Research, Год журнала: 2024, Номер 38, С. 1 - 1

Опубликована: Янв. 1, 2024

Язык: Английский

---